The Psychedelic Gold Rush: Big Pharma's Multi-Billion-Dollar Bet on Mind-Altering Therapies
Major pharmaceutical companies like Eli Lilly and AbbVie are making significant investments in psychedelic medicine, signaling a paradigm shift in mental health treatment. With compounds like DMT and psilocybin gaining FDA Breakthrough Therapy designation, the industry sees a multi-billion-dollar market. However, this commercialization raises critical questions about intellectual property, access, and the integrity of the therapeutic experience itself.